- What we do
-
-
Routes of delivery
- Oral
- Nasal
- Pulmonary
- Parenteral
-
Development stage
- Pre-clinical
- Phase I to Phase II
- Phase III - Commercial
Our Approach
- Project Management
-
- About us
-
-
A CDMO like no other
- About Us
- Our Facilities
- Our History
- Awards and Achievements
-
Leadership Expertise
- Executive Leadership Team
- Board of Directors
- Careers
-
-
- Resources
- Contact
Frequently Asked Questions.
What is Upperton's mission?
Passionate about science, we strive to build strong customer relationships and exceed their expectations. We develop and manufacture high-quality drug products and share in our customers’ dedication to change the lives of patients.
What are Upperton's values?
Our team is made of industry experts and bright talent who are passionate about advancing science. Our values shape our culture and how we do business.
United in advancing science
Passionate about helping people
Professional, quality-led service
Enthusiastic Problem Solvers
Respected industry leaders
Trusted to deliver
Opportunity to grow
Nurturing a supporting and collaborative environment
How long has Upperton been established?
Upperton was established in 1999 and has over 25 years of experience developing and manufacturing drug products, specialising in oral, nasal and pulmonary dosage forms. For more information about key milestones that have shaped the company today, visit our history page.
What potencies can you handle?
OEB4 and OEB5 projects depending on the processes involved. Speak with our technical team during a discovery call for more details.
What is your compliance with regulatory agencies?
Our development and manufacturing facility, Trent Gateway, is MHRA Approved (Medicines and Healthcare Products Regulatory Agency) and Home Office Approved.
Commissioning was completed in November 2023 with non-GMP activities commencing in January 2024. A mock MHRA inspection was conducted by EPIC in November 2024 with no major findings with MHRA Approval being granted in July 2024.
Our Albert Einstein Centre is a long-established GMP facility that underwent two MHRA inspections (December 2018 and July 2022) without any critical or major findings.
What types of dosage forms are you capable of working with?
Our development and manufacturing teams work across oral solid dosage forms, liquids, semi-solids, nasal and inhaled products.
Do you offer analytical method development and validation?
Yes, our dedicated 8,000 sqft quality control and analytical laboratories cater for traditional analytical techniques alongside characterisation techniques. View our analytical services page for more details.
Do you offer regulatory support services?
Yes, our regulatory affairs support service includes expert guidance, detailed documentation support regarding regulatory submissions, IND amendments and briefing packages.
Get in touch.
If you’re looking to work with a CDMO that is flexible and nimble, then we’re here to help.